dsip umich Welcome to D-SIP 2025-Project Showcase D-SIP at UMich (@dsipumich) •

doi: 10.1001/archinte.152.8.1611 [DOI] [PubMed] [Google Scholar] 147

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy

Osteogenic growth peptide (OGP) Studies have found that the naturally-occurring osteogenic growth peptide can increase bone formation and overall bone mass [5]

Cancer Res 82:CT108CT108 Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P et al (2020) Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Stockler MR, 2025, 'Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology , 26, pp